Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

 
Recent Webcast: Biodel to Report Fourth Quarter Fiscal Year 2013 Financial Results
December 18th, 2013
 
 
 
 
 
 
 
Biodel's proprietary drug-delivery technology is applicable to a wide range of peptides, proteins and other macromolecules. It allows us to alter the pharmacokinetic profile, route of administration and stability of drugs that otherwise would be impractical to use as therapeutics because they break down too rapidly.

 
Biodel's technology has important implications for the use of insulin, a large molecule which is absorbed into the blood relatively slowly. Biodel’s technology facilitates more natural and rapid absorption of recombinant human insulin and insulin analogs than current insulin products and appears to improve its therapeutic efficacy in patients with Type 1 and Type 2 diabetes.